Pharmaceutical company Accord BioPharma, Inc., the US division of Intas Pharmaceuticals, announced on Monday that it has received US FDA approval for IMULDOSA (ustekinumab-srlf), a biosimilar to STELARA.
IMULDOSA is approved to treat chronic inflammatory conditions such as psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis. STELARA generated USD10.86bn in global sales in 2023, highlighting strong market potential for IMULDOSA, which is expected to launch commercially in the US in early 2025.
This is Accord BioPharma's second FDA-approved biosimilar, following HERCESSI (trastuzumab-strf) earlier this year. IMULDOSA's approval is based on clinical data demonstrating its similarity to STELARA in pharmacokinetics, safety and efficacy.
Initially developed by Dong-A Socio Holdings and Meiji Seika Pharma, IMULDOSA's US commercialization rights were acquired by Intas Pharmaceuticals in 2021. Accord BioPharma plans to introduce more biosimilars in the US over the next five years.
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
Anixa Biosciences administers second dose of CAR-T therapy to individual patient
RevOpsis Therapeutics receives SBIR grant of over USD1.8m
AtomVie Global Radiopharma partners with Radiopharm Ventures
Lipella granted patent for innovative drug delivery technology
Adocia patents stable hormone combinations for obesity and diabetes
Accord BioPharma's IMULDOSA receives US FDA approval to treat chronic inflammatory conditions
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA
Quest Diagnostics acquires OhioHealth lab assets
Exelixis and Merck collaborate on clinical development of zanzalintinib
BD launches automated reagent kit to streamline single-cell discovery studies
Transgene's Phase II trial of TG4001 falls short of primary objective
GSK reports positive Phase III results for depemokimab in chronic rhinosinusitis with nasal polyps
SkylineDx reveals new data from the MERLIN_001 prospective US multi-centre trial